# EyePoint Pharmaceuticals
---
Who / What
EyePoint Pharmaceuticals is an American pharmaceutical company specializing in the development of drug delivery systems leveraging microelectromechanical systems (MEMS) and nanotechnology. The firm focuses on innovative approaches to enhance therapeutic efficacy, precision dosing, and patient compliance through advanced material science.
---
Background & History
EyePoint Pharmaceuticals traces its origins to **pSivida Corporation**, a company established in the early 2000s with a focus on porous silicon technology—a breakthrough developed from collaborations with the British government’s Defence Evaluation and Research Agency (DERA, now part of QinetiQ). The technology was initially applied to medical devices before being repurposed for pharmaceutical applications. In 2019, pSivida rebranded as EyePoint Pharmaceuticals, shifting its emphasis entirely toward drug delivery innovations.
---
Why Notable
EyePoint’s work in MEMS and nanotechnology holds significant potential to revolutionize the pharmaceutical industry by addressing challenges like drug stability, targeted delivery, and reduced side effects. The company’s proprietary porous silicon platform is particularly notable for enabling controlled-release formulations that could improve treatment adherence and patient outcomes. Its research has attracted attention from both academia and biotech investors due to its interdisciplinary approach, combining materials science with pharmacology.
---
In the News
As of recent reports, EyePoint Pharmaceuticals continues to explore partnerships and clinical trials aimed at advancing its drug delivery technologies. The company’s focus on precision medicine and novel formulations has kept it relevant in an evolving pharmaceutical landscape, particularly amid growing interest in personalized treatments and nanotechnology-driven innovations.
---
Key Facts
---
